Portal Biotechnologies
Portal Biotechnologies is a Watertown, Massachusetts-based cell-engineering platform company founded in 2023 by SQZ Biotechnologies founder Armon Sharei.
About
Portal Biotechnologies is a Watertown, Massachusetts-based cell-engineering platform company founded in 2023 by SQZ Biotechnologies founder Armon Sharei. It builds mechanical intracellular delivery devices that push mRNA, siRNA, polypeptides and CRISPR RNP complexes into living cells for research, drug discovery and therapeutic applications.
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Portal Biotechnologies
Portal Biotechnologies is a Watertown, Massachusetts-based cell-engineering platform company founded in 2023 by SQZ Biotechnologies founder Armon Sharei. It builds mechanical intracellular delivery devices that push mRNA, siRNA, polypeptides and CRISPR RNP complexes into living cells for research, drug discovery and therapeutic applications.
$5M
$5M
United States
BusinessLatest roundTotal raisedDate- RyboDyn
AI-driven sequencing and discovery platform decoding the "dark proteome" to find cancer-specific cryptic targets in patient tumors that conventional methods miss, for first-in-class cancer immunotherapies
Seed · $14M · 2026-03
$14M - Noetik
AI-based drug discovery, cancer immunology
Seed · $14M · 2023-09
$14M - QbDVision
Digital CMC platform for pharma and biotech companies, streamlining drug development through structured workflows
Undisclosed · $13M · 2025-05
$13M
China
BusinessLatest roundTotal raisedDate- Coherence Biotech Co. Ltd.
Lab automation: the Keystone™ benchtop all-in-one system combines culturing, intervention and microscopy imaging into uninterrupted multi-day cell/organoid experiments and uses AI vision to identify, count and track cells, generating structured experimental data for AI drug discovery
— - Insilico Medicine
AI drug discovery company that uses generative models for target discovery and molecular design, and has advanced multiple drug candidates into clinical trials
Series D+ · $210M · 2025-03
$210M - TandemAI
Drug molecule discovery platform rebuilt around "AI + physics-based modeling + wet lab"
Series A · $80M · 2025-11
$80M
Europe
BusinessLatest roundTotal raisedDate- Sightera Biosciences
AI-native drug discovery: patient-derived disease models and generative AI to design small-molecule cancer/fibrosis therapies
Pre-Seed · $3M · 2026-07
$3M - Perceptic
AI agents that connect research, clinical and operational data for pharma in drug discovery, trial design and asset evaluation
Seed · $12M · 2026-05
$12M - Bio Protocol
Funds and accelerates drug discovery through decentralized research agents
Seed · $7M · 2025-09
$7M
Other / unspecified
BusinessLatest roundTotal raisedDate- Scispot
Lab operating system for biotech and pharmaceutical labs
Series A · $10M · 2026-06
$10M - Reliant AI
Uses generative AI to help biopharma companies organize and analyze data for clinical trials or scientific publications
Seed · $11M · 2024-08
$11M - Intrepid Labs
Autonomous labs combining AI, robotics and chemistry to accelerate drug compound formulation
Seed · $11M · 2025-05
$11M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Andreessen Horowitz
24 Life Sciences deals in the last 24 months · 22 in North America
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.